{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:53:07Z","timestamp":1771210387083,"version":"3.50.1"},"reference-count":38,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"crossref","award":["U01-NS-044876-07"],"award-info":[{"award-number":["U01-NS-044876-07"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA). This report provides detailed results on the metabolic effects of pioglitazone and the trial\u2019s prespecified secondary aim of diabetes prevention.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>A total of 3,876 patients with recent ischemic stroke or TIA, no history of diabetes, fasting plasma glucose (FPG) &amp;lt;126 mg\/dL, and insulin resistance by homeostasis model assessment of insulin resistance (HOMA-IR) score &amp;gt;3.0 were randomly assigned to pioglitazone or placebo. Surveillance for diabetes onset during the trial was accomplished by periodic interviews and annual FPG testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>At baseline, the mean FPG, HbA1c, insulin, and HOMA-IR were 98.2 mg\/dL (5.46 mmol\/L), 5.8% (40 mmol\/mol), 22.4 \u03bcIU\/mL, and 5.4, respectively. After 1 year, mean HOMA-IR and FPG decreased to 4.1 and 95.1 mg\/dL (5.28 mmol\/L) in the pioglitazone group and rose to 5.7 and 99.7 mg\/dL (5.54 mmol\/L), in the placebo group (all P &amp;lt; 0.0001). Over a median follow-up of 4.8 years, diabetes developed in 73 (3.8%) participants assigned to pioglitazone compared with 149 (7.7%) assigned to placebo (hazard ratio [HR] 0.48 [95% CI 0.33\u20130.69]; P &amp;lt; 0.0001). This effect was predominately driven by those with initial impaired fasting glucose (FPG &amp;gt;100 mg\/dL [5.6 mmol\/L]; HR 0.41 [95% CI 0.30\u20130.57]) or elevated HbA1c (&amp;gt;5.7% [39 mmol\/mol]; HR 0.46 [0.34\u20130.62]).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc16-0798","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T22:38:54Z","timestamp":1469659134000},"page":"1684-1692","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":69,"title":["Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease"],"prefix":"10.2337","volume":"39","author":[{"given":"Silvio E.","family":"Inzucchi","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Viscoli","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Young","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Furie","sequence":"additional","affiliation":[{"name":"Alpert Medical School of Brown University, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gorman","sequence":"additional","affiliation":[{"name":"Vermont College of Medicine, Burlington, VT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Lovejoy","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Dagogo-Jack","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faramarz","family":"Ismail-Beigi","sequence":"additional","affiliation":[{"name":"Case Western Reserve University and VA Medical Center, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary T.","family":"Korytkowski","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[{"name":"Florida Hospital, Orlando, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"VA Medical Center and University of Colorado School of Medicine, Denver, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter N.","family":"Kernan","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the IRIS Trial Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"key":"2022031123360575900_B1","unstructured":"International Diabetes Foundation. IDF Diabetes Atlas. 7th ed. Available from www.diabetesatlas.org. Accessed 9 April 2016"},{"key":"2022031123360575900_B2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ecl.2004.11.008","article-title":"The prevention of type 2 diabetes mellitus","volume":"34","author":"Inzucchi","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2022031123360575900_B3","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.2337\/dc14-0817","article-title":"We can change the natural history of type 2 diabetes","volume":"37","author":"Phillips","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031123360575900_B4","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.2337\/dc09-S302","article-title":"Skeletal muscle insulin resistance is the primary defect in type 2 diabetes","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031123360575900_B5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031123360575900_B6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2014.07.016","article-title":"Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial","volume":"168","author":"Viscoli","year":"2014","journal-title":"Am Heart J"},{"key":"2022031123360575900_B7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031123360575900_B8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2022031123360575900_B9","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031123360575900_B10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031123360575900_B11","unstructured":"FDA Drug Safety Communication. Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [Internet], 2013. Available from http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm226257.htm. Accessed 9 April 2016"},{"key":"2022031123360575900_B12","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.27.2007.S5","article-title":"Diagnosis and classification of diabetes mellitus","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031123360575900_B13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/193229680900300446","article-title":"Glucose meters: a review of technical challenges to obtaining accurate results","volume":"3","author":"Tonyushkina","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"2022031123360575900_B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc [Ser A]"},{"key":"2022031123360575900_B15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2022031123360575900_B16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni Procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"2022031123360575900_B17","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"2022031123360575900_B18","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc16-S005","article-title":"Classification and diagnosis of diabetes","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031123360575900_B19","unstructured":"World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO\/IDF Consultation. [Internet], 2006. Available from http:\/\/www.who.int\/diabetes\/publications\/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 9 April 2016"},{"key":"2022031123360575900_B20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program","volume":"54","author":"Knowler","year":"2005","journal-title":"Diabetes"},{"key":"2022031123360575900_B21","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"Gerstein","year":"2006","journal-title":"Lancet"},{"key":"2022031123360575900_B22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031123360575900_B23","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"2022031123360575900_B24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2337\/dc10-1567","article-title":"Incidence of diabetes following ramipril or rosiglitazone withdrawal","volume":"34","author":"DREAM Trial Investigators","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031123360575900_B25","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1210\/jc.2015-4202","article-title":"Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: Results from ACT NOW","volume":"101","author":"Tripathy","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031123360575900_B26","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"2022031123360575900_B27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrendo.2014.29","article-title":"Insulin resistance and hyperglycaemia in cardiovascular disease development","volume":"10","author":"Laakso","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"2022031123360575900_B28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031123360575900_B29","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"2022031123360575900_B30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/ATVBAHA.112.300346","article-title":"Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors","volume":"33","author":"Saremi","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031123360575900_B31","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1111\/bph.13029","article-title":"The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges","volume":"172","author":"Cheang","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2022031123360575900_B32","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI23705","article-title":"PPARs in atherosclerosis: the clot thickens","volume":"114","author":"Castrillo","year":"2004","journal-title":"J Clin Invest"},{"key":"2022031123360575900_B33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf"},{"key":"2022031123360575900_B34","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"2022031123360575900_B35","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1093\/eurheartj\/ehv301","article-title":"Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database","volume":"36","author":"Fadini","year":"2015","journal-title":"Eur Heart J"},{"key":"2022031123360575900_B36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"2022031123360575900_B37","first-page":"i1541","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume-title":"BMJ","author":"Tuccori","year":"2016"},{"key":"2022031123360575900_B38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc14-2098","article-title":"Determinants of adherence to diabetes medications: findings from a large pharmacy claims database","volume":"38","author":"Kirkman","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc16-0798","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/10\/1684\/625457\/dc160798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/10\/1684\/625457\/dc160798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T10:32:34Z","timestamp":1718706754000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/10\/1684\/158\/Pioglitazone-Prevents-Diabetes-in-Patients-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,7,27]]},"published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-0798","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,27]]}}}